Lisa Bollinger - 09 Jun 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Jun 2026, 20:00:07 UTC
Prior SEC filing
29 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Matthew Batters, as attorney-in-fact for Lisa Bollinger

Key filing fact

Lisa Bollinger filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 11 Jun 2026.

Key facts

  • This page summarizes Lisa Bollinger's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 11 Jun 2026, 20:00.

Change

  • Previous filing in this sequence was filed on 29 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002024557 Primary reporting owner

Bollinger Lisa

Relationship
Director
Address
C/O APOGEE THERAPEUTICS, INC., 221 CRESCENT ST., BLDG. 17, STE. 102B, WALTHAM
Signature
/s/ Matthew Batters, as attorney-in-fact for Lisa Bollinger
Signature date
11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+7,657
Change %
Price
$0.000000*
Shares after
7,657
Date
09 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,657
Exercise price
$85.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .